Findings from STELLAR Phase III Trial Presented at ACC23 Report Novel First-in-class Medication Shows Promise in Treating Rare Heart Lung Condition

Significant improvements in six-minute walking distance were reported in the STELLAR Phase III Trial whose findings were unveiled during a Featured Clinical Research session on the final day of the March 4-6 American College of Cardiology Scientific Session, ACC23 Together with WCC. Researchers added a novel first-in-class medication in combination with background therapy in patients with pulmonary arterial hypertension (PAH), a severe, progressive condition that affects the heart and lungs.

Related Keywords

Germany ,United States ,Boston ,Massachusetts ,Mariusm Hoeper ,Jane Leopold ,American College Of Cardiology ,Hannover Medical School In ,Merck Co ,Harvard Medical School Boston ,Department Of Respiratory Medicine ,Women Interventional Cardiology Health Initiative At Brigham ,Acceleron Pharma Inc ,American College ,Background Therapy ,Pulmonary Arterial ,New England Journal ,Deputy Director ,Respiratory Medicine ,Hannover Medical School ,Merck Sharp ,Landmark Trial ,Interventional Cardiology Health Initiative ,Harvard Medical School ,